Skip to main content

Table 4 Percentage of enriched participants for each direct comparison

From: Using the contribution matrix to evaluate complex study limitations in a network meta-analysis: a case study of bipolar maintenance pharmacotherapy review

Direct comparisons
  PLB vs LIT PLB vs VPA PLB vs LTG PLB vs IMP PLB vs FLX PLB LIT+IMP PLB
vs ARP
PLB vs OLZ PLC
vs QTP
PLB RisLAI PLB vs PAL LIT vs VPA LIT vs CBZ LIT vs LTG LIT vs IMP LIT vs LX LIT vs LIT+IMP LIT
vs LIT+VPA
LIT vs LIT+OXC LIT vs OLZ LIT vs QTP VPA vs LIT+VPA VPA vs VPA+ARP LTG vs VPA+LTG LTG vs ARP+LTG IMP vs LIT+IMP OLZ vs RisLAl
Manic
(%)
0 0 29 0 0 100 58 42 72 100 0 0 26 0 22 0 0 0 72 0 100 0 100 41 100
Depression (%) 0 0 79 0 100 0 0 0 58 0 0 0 0 76 0 100 25 0 0 0 28 0 0 100 0 46 0
  1. ARP aripiprazole, CBZ carbamazepine, FLX fluoxetine, IMP imipramine, LIT lithium, LTG lamotrigine, OLZ olanzapine, OXC oxcarbazepine, PAL paliperidone, PLB placebo, QTP quetiapine, RisLAI risperidone long-acting injection, VPA valproate